Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Christine Manderscheid"'
Autor:
Ellen Niederberger, Annett Wilken-Schmitz, Christine Manderscheid, Yannick Schreiber, Robert Gurke, Irmgard Tegeder
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 20; Pages: 12658
Oral rotenone has been proposed as a model for Parkinson’s disease (PD) in mice. To establish the model in our lab and study complex behavior we followed a published treatment regimen. C57BL/6 mice received 30 mg/kg body weight of rotenone once dai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d89b012404dec70881859527df07bd
https://doi.org/10.3390/ijms232012658
https://doi.org/10.3390/ijms232012658
Autor:
Christoph Renné, Laura Popp, Gerd Geisslinger, Claudiu Marian, Christine Manderscheid, Ellen Niederberger, Ronald Schmidt, Rudi Busse, Ingrid Fleming, Beate Fisslthaler, Julia Metzner
Publikováno v:
Journal of Molecular Medicine. 85:623-633
In this study, we investigated the effects of prolonged administration of the selective COX-2 inhibitors celecoxib and rofecoxib and the non-selective NSAID naproxen on the initiation and progression of atherosclerosis. ApoE(-/-) mice, as well as cor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0811ec0e503fe083d53e968d5499e0bd
https://doi.org/10.1007/s00109-007-0162-9
https://doi.org/10.1007/s00109-007-0162-9
Autor:
Christine Manderscheid, Sabine Grösch, Gerd Geisslinger, Helmut Schmidt, Corina Ehnert, Ellen Niederberger
Publikováno v:
Biochemical Pharmacology. 68:341-350
Rheumatoid arthritis (RA) is associated with a reduced life expectancy considered to be partly caused by cardiovascular events. A growing concern is that accelerated atherosclerosis is driven by inflammatory mechanisms similar to those responsible fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182c39c0a182da9019d59199e01b3097
https://doi.org/10.1016/j.bcp.2004.03.029
https://doi.org/10.1016/j.bcp.2004.03.029
Publikováno v:
Biochemical and biophysical research communications. 342(3)
Etoricoxib and lumiracoxib are both highly selective COX-2 inhibitors. This drug class has recently been linked to severe side effects in particular within the cardiovascular system. The underlying signal transduction pathway is not clarified at the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202f1a0e7fba5a4d10aa542bd5392ab0
https://pubmed.ncbi.nlm.nih.gov/16598848
https://pubmed.ncbi.nlm.nih.gov/16598848